Print

Enzon (ENZN) And Pharmagene Announce Agreement To Develop PEGylated Secretin For Cystic Fibrosis 
10/19/2005 5:11:24 PM

Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) and Pharmagene plc (LSE:PGN) announced today they have signed an agreement for the development of a long-acting version of Pharmagene's drug candidate, PGN0052. PGN0052 is a peptide hormone that is initially being investigated as a treatment for cystic fibrosis and may have additional applications for other respiratory disorders.